1. Home
  2. KBDC vs ACHV Comparison

KBDC vs ACHV Comparison

Compare KBDC & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kayne Anderson BDC Inc.

KBDC

Kayne Anderson BDC Inc.

SELL

Current Price

$13.00

Market Cap

822.8M

Sector

N/A

ML Signal

SELL

Logo Achieve Life Sciences Inc.

ACHV

Achieve Life Sciences Inc.

SELL

Current Price

$6.97

Market Cap

726.5M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
KBDC
ACHV
Founded
2021
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
822.8M
726.5M
IPO Year
2018
2018

Fundamental Metrics

Financial Performance
Metric
KBDC
ACHV
Price
$13.00
$6.97
Analyst Decision
Buy
Strong Buy
Analyst Count
5
12
Target Price
★ $14.50
$14.15
AVG Volume (30 Days)
398.5K
★ 1.3M
Earning Date
11-05-2026
11-17-2026
Dividend Yield
★ 12.31%
N/A
EPS Growth
N/A
★ N/A
EPS
★ 0.85
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$15.29
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$12.14
$2.62
52 Week High
$15.87
$8.64

Technical Indicators

Market Signals
Indicator
KBDC
ACHV
Relative Strength Index (RSI) 53.25 45.21
Support Level $12.88 $5.96
Resistance Level $13.65 $7.30
Average True Range (ATR) 0.28 0.40
MACD 0.07 0.03
Stochastic Oscillator 76.00 47.66

Price Performance

Historical Comparison
KBDC
ACHV

About KBDC Kayne Anderson BDC Inc.

Kayne Anderson BDC Inc is an externally managed, closed-end, non-diversified management investment company that has elected to be regulated as a business development company, investing mainly in first-lien senior secured loans, with a secondary focus on unitranche and split-lien loans to middle-market companies. Its investment objective is to generate current income and, to a lesser extent, capital appreciation mainly through debt investments in middle-market companies.

About ACHV Achieve Life Sciences Inc.

Achieve Life Sciences Inc is a late-stage clinical specialty pharmaceutical company with the sole mission to address the nicotine dependence epidemic through the development and commercialization of cytisinicline. Cytisinicline, is a naturally occurring alkaloid. Additionally, The company has completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication. It operates in one operating segment, development and commercialization of cytisinicline for nicotine dependence, with operations located in Canada, the United States and the U.K.

Share on Social Networks: